Met Life Investment Management, LLC Taysha Gene Therapies, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 62,990 shares of TSHA stock, worth $114,641. This represents 0.0% of its overall portfolio holdings.
Number of Shares
62,990
Previous 76,037
17.16%
Holding current value
$114,641
Previous $152,000
28.95%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding TSHA
# of Institutions
128Shares Held
150MCall Options Held
48KPut Options Held
7.8K-
Avoro Capital Advisors LLC New York, NY20MShares$36.4 Million0.5% of portfolio
-
Morgan Stanley New York, NY17.6MShares$32.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$21.4 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$19.8 Million0.3% of portfolio
-
Octagon Capital Advisors LP New York, NY10.5MShares$19 Million4.03% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $88M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...